Jake Jorgovan

JANUARY 30, 2024

The Biopharma industry is always evolving. However, thought leaders in the Biopharma industry offer innovative insights and strategic direction. You're on the right page to find these experts; we’ll discuss Biopharma's top 12 thought leaders, highlighting their unique expertise and what they can teach you. Let’s dive in.

Biopharma 130

Biopharma Life science Biotech Biopharmaceuticals 130

Vantage Partners

JANUARY 19, 2024

Activity among Big Pharmas in 2023 ( Merck + Prometheus ; Pfizer + Seagen ) dominated headlines, and major deal announcements around this year's JPM Healthcare conference (including Merck's acquisition of Harpoon Therapeutics , J&J's acquisition of Ambrx , and GSK's acquisition of Aiolos Bio ) present signals that this trend will only continue (..)

Biopharma 83

Biopharma Life science Alliance partnership 83

Frost & Sullivan

JUNE 24, 2024

The sessions of the American Society of Clinical Oncology ( ASCO ) 2024 conference focused on this year’s theme – The Art and Science of Cancer Care: From comfort to cure. During ASCO 2024, AbbVie unveiled new data from its ADC platform, which is now being used for the development of therapies that specifically target solid tumors.

Biopharmaceuticals 52

Biopharmaceuticals Biopharma Collaboration Ecosystems 52

Frost & Sullivan

AUGUST 29, 2024

However, the pharma/biopharma industry overall shows stagnant R&D activity. growth from 2023 to 2024. Conversely, small-to-mid, and emerging biopharma players, with 1 or 2 molecules in the pipeline, contribute over 16%. increase from 2022. Total R&D expenditure is approximately $276.81 billion, with a modest 2.5%

Biopharma 52

Biopharma Biotechnology Contract research organization Utilities 52

LaVoie Health Science Blog

FEBRUARY 7, 2024

We are excited to experience Katie’s leadership with our team and clients, who are dedicated to advancing health and science innovations globally.”

Biopharma 52

Biopharma Life science 52

Frost & Sullivan

MARCH 22, 2024

However, the pharma/biopharma industry shows overall stagnant R&D activity. growth from 2023 to 2024. What is driving transformation in the pharma industry? Small-to-mid and emerging biopharma players contribute over 16%. increase from 2022. Total R&D expenditure is approximately $276.81 billion, with a modest 2.5%

Ecosystems 52

Ecosystems Biopharma Biotech Contract research organization 52

Frost & Sullivan

APRIL 3, 2024

The Drug, Chemical & Associated Technologies Association (DCAT) 2024 event held in New York City on March 18-21 showcased product and technology innovations and capabilities presentations by member companies. in January 2024 further enhanced its portfolio of complex drug-device combination products.

Biopharmaceuticals 59

Biopharmaceuticals Biopharma Biotechnology Life science 59